This listing of claims will replace all prior versions of the claims in this application:

Listing of Claims:

1. (Currently Amended) A composition comprising a pharmacon incorporated into a fructan having a number-average degree of polymerization of at least ~~6~~ 7 in the form of a sugar glass.

2. (Previously Presented) The composition according to claim 1, wherein the fructan has a number-average degree of polymerization of at least 10.

3. (Previously Presented) The composition according to claim 1, wherein the fructan is inulin.

4. (Currently Amended) A method for stabilizing a pharmacon, comprising incorporating a pharmacon in a sugar glass of a fructan having a number-average degree of polymerization of at least ~~6~~ 7.

5. (Previously Presented) The method for stabilizing a pharmacon according to claim 4, wherein the fructan has a number-average degree of polymerization of at least 10.

6. (Previously Presented) The method for stabilizing a pharmacon according to claim 4, wherein the fructan is inulin.

7. (Previously Presented) The method for stabilizing a pharmacon according to claim 4, wherein the step of incorporating a pharmacon comprises forming a solution comprising a fructan and a pharmacon and drying the solution to form a sugar glass.

8. (Currently Amended) A composition produced by a process comprising incorporating a pharmacon into a sugar glass of a fructan having a number-average degree of polymerization of at least ~~6~~ 7.

9. (Currently Amended) A pharmaceutical preparation comprising a pharmacon incorporated into a sugar glass of a fructan having a number-average degree of polymerization of at least ~~6~~ 7.

10. (Previously Presented) The pharmaceutical preparation according to claim 9 in the form of a tablet, capsule, lozenge, dermatic, suppository, powder for pulmonary administration, or a rod or suspension for subcutaneous or intramuscular administration.

11. (Currently Amended) A method for producing a bioavailable form of a pharmacon in a pharmaceutical preparation comprising incorporating a pharmacon into sugar glass of a fructan having a number-average degree of polymerization of at least ~~6~~ 7, wherein the bioavailability of the pharmacon is thereby increased.

12. (Canceled)

13. (Previously Presented) The method for stabilizing a pharmacon according to claim 4, wherein the fructan is a glucan.

14. (Previously Presented) The method for stabilizing a pharmacon according to claim 4, wherein the fructan is levan.

15. (Previously Presented) The method for stabilizing a pharmacon according to claim 4, wherein the pharmacon is an active substance.

16. (Previously Presented) The method for stabilizing a pharmacon according to claim 4, wherein the pharmacon is selected from the group comprising: DNA, RNA, nucleotide,

oligosaccharide, protein, peptide, amino acid, vitamin, lipid, hormone, enzyme, growth factor, antibody, antigen, metabolites of the above, and mixtures of the above.

17. (Previously Presented) The method for stabilizing a pharmacon according to claim 7, wherein the solution is dried by spray-drying.

18. (Previously Presented) The method for stabilizing a pharmacon according to claim 17, wherein the spray-drying produces spherical particles from between 1 to 5 μm.

19. (Previously Presented) The method for stabilizing a pharmacon according to claim 7, wherein the solution is dried by vacuum drying.

20. (Previously Presented) The method for stabilizing a pharmacon according to claim 7, wherein the solution is dried by freeze drying.

21. (Previously Presented) A pharmacon according to claim 8, wherein the pharmacon is an active substance.

22. (Previously Presented) A pharmacon according to claim 8, wherein the pharmacon is selected from the group comprising: DNA, RNA, nucleotide, protein, peptide, amino acid, oligosaccharide, vitamin, lipid, hormone, enzyme, growth factor, antibody, antigen, metabolites of the above, and mixtures of the above.